trending Market Intelligence /marketintelligence/en/news-insights/trending/0W2rFjTOUblr2ynXDm4Ehw2 content esgSubNav
In This List

OncoSec undertakes 1-for-10 reverse stock split

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


OncoSec undertakes 1-for-10 reverse stock split

Pennington, N.J.-based cancer drug developer OncoSec Medical Inc.'s board approved a 1-for-10 reverse stock split of its common stock, effective May 20.

The move reduced the company's issued and outstanding common shares to about 7 million from approximately 70 million.

OncoSec's shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market under the ticker ONCS, effective May 21.